Report
Pharmaceuticals ASCO 2020: No revolution at first glance but interesting data to watch in lung cancer
PharmaceuticalsASCO 2020: No revolution at first glance but interesting data to watch in lung cancer
Tagrisso expected to benefit strongly from ADAURA
Is KN-799 threat or hope for Imfinzi in stage III NSCLC ?
Should Enhertu be considered in NSCLC?
Tiragolumab: how good is the first TIGIT ICI?
AZ expected to be the winner of ASCO 2020
Provider
Bryan Garnier
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Eric Le Berrigaud
Other Reports from Bryan Garnier
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.